Externally-led Patient-Focused Drug Development Meeting for SCN2A-Related Disorders
Posted authors: Katie Friedman, BS, and Morgan Weberg, BS Dear SCN2A Community, Our community, including staff, volunteers, and parent and
Understanding a New Publication on Antisense Oligonucleotide (ASO) Treatments for SCN2A-Related Disorders
Post authored by: Jeffrey Cottrell, PhD; Perry Spratt, PhD; Morgan Weberg, BS Link to Publication Dear SCN2A Community, A recent
National Genetic Testing Action Day (NGTAD) – July 25, 2026
Authored by: Elizabeth L. Lyon, MS, CGC, LGC Contributions by: Leah Schust Myers, Melody Kisor, Amanda Gale, Katelin Scott, Jenny
Understanding a New Zebrafish Publication on LevocarnitineÂ
Post authored by: Jeff Cottrell, PhD, Morgan Weberg, BS, and Melody Kisor, MS, BCPA A recent research study published in
April 2026 – Updates on the SCN2A Drug Development Pipeline
Dear SCN2A Community, Everything starts with a committed and engaged community. The trust you place in us to share updates,
Reflections from AES: Collaboration, Momentum, and What’s Ahead for SCN2A
Photo: Jeff Cottrell – Interim Chief Scientific Officer, Leah Myers – Executive Director, Angie Weaver – Director of Philanthropy & Development, Amanda Gale –
Updates on the SCN2A Clinical Trial and Treatment PipelineÂ
The FamilieSCN2A Team: Amanda Gale – Program Manager, Angie Weaver – Director of Philanthropy & Development, Leah Myers – Executive
The FamilieSCN2A Foundation Response to Recent Autism News
“In light of this week’s public comments and media discussion about the causes and management of autism, we want you…
What to Expect When Considering a Clinical Trial: Clinical Research 101
Thinking about participating in a clinical trial, but not sure what it really means for your child and your family?
From Advocacy to Action: SCN2A Now Has Its Own ICD-10 Code
The FamilieSCN2A Foundation is thrilled to announce that advocacy efforts with the CDC over the last four years have resulted